Panacea Biotec Ltd
Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company[1]
- Market Cap ₹ 2,618 Cr.
- Current Price ₹ 427
- High / Low ₹ 582 / 259
- Stock P/E
- Book Value ₹ 136
- Dividend Yield 0.00 %
- ROCE -4.68 %
- ROE -5.03 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Stock is trading at 3.14 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 0.55% over past five years.
- Company has a low return on equity of -6.40% over last 3 years.
- Earnings include an other income of Rs.67.1 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
510 | 687 | 653 | 544 | 593 | 457 | 544 | 625 | 661 | 460 | 559 | 559 | 610 | |
582 | 643 | 541 | 505 | 509 | 591 | 490 | 548 | 674 | 558 | 579 | 585 | 623 | |
Operating Profit | -72 | 44 | 112 | 39 | 84 | -134 | 54 | 77 | -13 | -98 | -20 | -26 | -13 |
OPM % | -14% | 6% | 17% | 7% | 14% | -29% | 10% | 12% | -2% | -21% | -4% | -5% | -2% |
183 | 28 | 70 | 62 | 8 | 338 | -14 | 9 | 1,687 | 154 | 62 | 57 | 67 | |
Interest | 150 | 105 | 127 | 101 | 101 | 105 | 174 | 185 | 181 | 4 | 4 | 4 | 4 |
Depreciation | 71 | 67 | 73 | 68 | 57 | 54 | 43 | 46 | 44 | 39 | 37 | 35 | 34 |
Profit before tax | -111 | -99 | -19 | -67 | -66 | 45 | -178 | -146 | 1,449 | 13 | 1 | -8 | 16 |
Tax % | 2% | 3% | 10% | -16% | 15% | 17% | 9% | 1% | 26% | 363% | 201% | 10% | |
-113 | -108 | -21 | -56 | -76 | 38 | -194 | -148 | 1,078 | -34 | -2 | -9 | 11 | |
EPS in Rs | -18.29 | -17.38 | -2.98 | -8.89 | -12.07 | 6.15 | -31.69 | -24.09 | 175.91 | -5.42 | -0.19 | -1.37 | 1.87 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -2% |
5 Years: | 1% |
3 Years: | -5% |
TTM: | 12% |
Compounded Profit Growth | |
---|---|
10 Years: | 5% |
5 Years: | 12% |
3 Years: | 21% |
TTM: | 29% |
Stock Price CAGR | |
---|---|
10 Years: | 13% |
5 Years: | 18% |
3 Years: | 46% |
1 Year: | 36% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -6% |
Last Year: | -5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
Reserves | 507 | 449 | 426 | 350 | 303 | 344 | 193 | -235 | 871 | 837 | 836 | 829 |
1,060 | 1,111 | 1,105 | 994 | 941 | 646 | 742 | 820 | 34 | 20 | 21 | 22 | |
371 | 364 | 317 | 440 | 349 | 379 | 449 | 587 | 848 | 407 | 378 | 433 | |
Total Liabilities | 1,943 | 1,930 | 1,854 | 1,789 | 1,598 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 |
1,276 | 1,144 | 1,071 | 1,001 | 949 | 806 | 657 | 609 | 622 | 600 | 582 | 601 | |
CWIP | 172 | 155 | 161 | 30 | 40 | 23 | 24 | 34 | 17 | 42 | 102 | 94 |
Investments | 16 | 15 | 9 | 7 | 7 | 5 | 6 | 0 | 5 | 13 | 40 | 3 |
479 | 616 | 614 | 750 | 602 | 542 | 703 | 534 | 1,114 | 615 | 517 | 592 | |
Total Assets | 1,943 | 1,930 | 1,854 | 1,789 | 1,598 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
54 | 37 | 91 | 131 | 118 | 105 | -30 | 107 | -108 | -422 | -0 | -27 | |
-38 | -37 | 16 | -26 | 55 | -6 | -35 | -48 | 1,283 | 430 | 10 | 65 | |
-30 | -1 | -117 | -107 | -164 | -101 | 91 | -47 | -1,176 | -18 | -3 | -3 | |
Net Cash Flow | -14 | -1 | -10 | -2 | 9 | -2 | 26 | 12 | -2 | -10 | 7 | 35 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 68 | 52 | 79 | 95 | 84 | 71 | 46 | 49 | 45 | 48 | 37 | 47 |
Inventory Days | 375 | 404 | 516 | 770 | 651 | 173 | 344 | 311 | 296 | 292 | 282 | 391 |
Days Payable | 430 | 272 | 318 | 607 | 540 | 572 | 463 | 440 | 327 | 256 | 244 | 413 |
Cash Conversion Cycle | 13 | 184 | 278 | 259 | 195 | -328 | -73 | -80 | 14 | 83 | 76 | 25 |
Working Capital Days | -343 | -126 | 27 | -46 | -96 | -363 | 95 | -43 | -229 | -5 | -2 | 46 |
ROCE % | -8% | 0% | 4% | 2% | 3% | -16% | 4% | 5% | -6% | -10% | -4% | -5% |
Documents
Announcements
-
Communication Sent To Physical Shareholders To Furnish PAN And KYC Details
2d - Reminder sent Sept 19, 2025 requesting physical shareholders to update PAN, KYC, bank details and dematerialize holdings.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Sep - Newspaper copies regarding advertisement of Notice of 41st Annual General Meeting, Cut-off Date and Remote e-voting information, published on September 09, 2025.
- Demat Status Report For The Month Of August 2025 8 Sep
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
8 Sep - AGM on September 30, 2025 via VC; annual report and notice online; e-voting Sep 27–29.
-
Business Responsibility and Sustainability Reporting (BRSR)
8 Sep - Filed Business Responsibility & Sustainability Report for FY2024-25 on Sep 08, 2025; report link provided.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
Business Overview:[1]
a) PBL is in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food & nutrition products
b) It is one of the largest Vaccine Manufacturing Company in India and is acknowledged by the United Nations (UN) Health Agencies in partnering the Global Polio Eradication Initiative (GPEI) with supplies of billions of doses of WHO Pre-qualified Polio vaccines in 50+ countries worldwide as a sequel to the completion of full range of Oral polio vaccines (tOPV, mOPV1, mOPV3 & bOPV (Type1&Type3)
c) It is the first company to have developed fully liquid Pentavalent vaccine (DTwP-Hep B+Hib) EasyFive and world’s first fully-liquid wP-IPV based Hexavalent vaccine (DTwP +HepB +Hib +IPV) EasySix